---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-064739"
form_type: "8-K"
ticker: "CYPH"
cik: "0001509745"
company_name: "CYPHERPUNK TECHNOLOGIES INC."
filed_at: "2023-05-25T23:59:59+00:00"
generated_at: "2026-06-14T14:27:51.047128+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Leap Therapeutics reports 19.5-month median OS from DKN-01 combo in gastric cancer; data at ASCO 2023

## Summary
- Median OS 19.5 months, median PFS 11.3 months in first-line GEA patients (n=25), exceeding current benchmarks.
- ORR 73% in mITT population; 86% ORR in PD-L1-low patients; 90% ORR in DKK1-high patients.
- Additional partial response after 22 months of therapy; tumor reductions deepen over time.
- Part C randomized controlled trial enrolling; completion expected late 2023; colorectal data coming.

## SEC filing metadata
- accession: 0001104659-23-064739
- form_type: 8-K
- ticker: CYPH
- cik: 0001509745
- company_name: CYPHERPUNK TECHNOLOGIES INC.
- filed_at: 2023-05-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509745/000110465923064739/0001104659-23-064739-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509745/000110465923064739/tm2317022d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-064739
- JSON: https://secwatch.observer/filing/0001104659-23-064739.json
- Plain text: https://secwatch.observer/filing/0001104659-23-064739.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.